Skip to main content
Premium Trial:

Request an Annual Quote

New Study Finds miR-155 Controls CD8+ T Cells Via Interferon Regulation


A new study has identified a link between microRNA-155 and the immune system, showing that the small, non-coding RNA plays a key part in mediating the activity of CD8+ T cells against pathogens.

The findings, which appeared this week in Nature Immunology, pinpoints a previously unknown function for miR-155, and indicates that the miRNA controls the CD8+ T cells by regulating interferon signaling.

CD8+ T cells are a critical part of the adaptive immune system, providing immunity to a host of intracellular pathogens and malignant cells. Meanwhile, miRNAs have been shown to be important players in immunity, with studies showing impairment of CD4+ T cells lacking Dicer, for instance.

“However, the role of individual microRNAs in the CD8+ T cells response is largely unexplored,” the team wrote in Nature Immunology.

Looking to address this, the investigators focused their attention on miR-155 in light of earlier research establishing it as critical for the function of B and T lymphocytes and dendritic cells, while finding a “wide spectrum” of gene targets in CD4+ T cells, according to senior author and Babraham Institute researcher Martin Turner. The miRNA had also been previously implicated in B cell differentiation.

They began by looking at the effect the status of CD8+ T cells had on miR-155, and found that after in vitro stimulation, naive CD8+ T cells rapidly increased their expression of the miRNA. Further, miR-155 expression was significantly increased in CD8+ T cells isolated from the lungs of mice infected with influenza, all of which implicated the miRNA in regulating the T cells’ responses.

To extend their observations, the team then infected miR-155-deficient and wild-type mice with a sublethal dose of influenza. The miR-155-deficient mice showed a “much lower frequency and number” of lung-specific CD8+ T cells, as well as impaired viral clearance, versus their normal counterparts.

The researchers also examined whether miR-155 deficiency impacted CD8+ T cell responses to bacterial infection. In mice lacking the miRNA, CD8+ T cell levels were 15 times lower in response to Listeria monocytogenes infection than in control animals.

In addition to diminished primary CD8+ T cell responses, miR-155-deficient mice had significantly fewer memory cells versus their wild-type counterparts

“When we analyzed short-lived effector cells and memory precursor effector cells during the primary response, we found that miR-155 deficiency impaired the abundance of each population,” the researchers wrote. “These findings indicated that miR-155 was required for the establishment of a CD8+ T cell memory pool during pathogenic infection.”

Overall, miR-155 appears to have an “intrinsic role” in regulating primary CD8+ T cell responses to pathogens and affects establishment of memory CD8+ T cells, they added.

Having shown that miR-155 deficiency negatively affects CD8+ T cell responses, the investigators examined whether its overexpression would enhance immunity.

Indeed, in mice transduced with CD8+ T cells with a vector expressing miR-155 and infected with influenza, pulmonary CD8+ T cell populations expanded five times more than in infected animals transduced with a control vector. Mice receiving the miR-155 vector also had lower viral loads.

Through their work, the investigators also addressed an “unresolved paradox” concerning the role of type I interferon signaling in CD8+ T cells as a “critical costimulatory signal,” which contrasts its well-known antiproliferative effects, according to the Nature Immunology paper.

“It was already known that the interferon signaling pathway could inhibit the activation of CD8+ T cells,” Turner told Gene Silencing News, but the mechanism behind this is poorly understood. “We were thinking … [that] maybe the microRNA is involved in dampening or inhibiting that pathway.”

Gene-expression profiling conducted by the researchers showed that miR-155-deficient CD8+ T cells had enhanced type I interferon signaling and were more susceptible to interferon’s antiproliferative effect.

They also found that inhibiting the type I interferon-associated transcription factor STAT1 triggered enhanced responses of miR-155-deficient CD8+ T cells in vivo, suggesting that the miRNA may influence changes in responsiveness to type I interferon by acting on the STAT1 signaling pathway.

“The amount of miR-155 may also function as a key modulator of CD8+ T cell responses in the presence of type I interferons, determining whether type I interferons act as costimulatory signals or as inhibitors,” the team wrote.

Turner noted that in other cell types where miR-155 has “important biological consequences for cell function,” it appears that the miRNA does not affect the type I interferon pathway.

“It may be that microRNA-155 targets different pathways in a cell type-specific way to modulate the function of different cells,” he said.

“It seems clear that microRNA targets are context-dependent,” he added. “I think that’s quite an interesting idea.”

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.